Publications by authors named "Jonathan D Licht"

128 Publications

Histone H3 G34 Tail Mutations in Cancer: Actions in and to Alter Chromatin and Gene Expression.

Authors:
Jonathan D Licht

Cancer Discov 2020 Dec;10(12):1794-1796

University of Florida, Gainesville, Florida.

View Article and Find Full Text PDF
December 2020

Oncogenesis by E2A-PBX1 in ALL: RUNX and more.

Authors:
Jonathan D Licht

Blood 2020 07;136(1):3-4

The University of Florida.

View Article and Find Full Text PDF
July 2020

FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.

Nat Commun 2020 02 17;11(1):928. Epub 2020 Feb 17.

Division of Hematology/Oncology, UF Health Cancer Center, University of Florida, Gainesville, FL, USA.

View Article and Find Full Text PDF
February 2020

Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.

Cancer Lett 2020 04 31;475:99-108. Epub 2020 Jan 31.

Myeloma Research Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia; Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia. Electronic address:

View Article and Find Full Text PDF
April 2020

Decitabine limits escape from MEK inhibition in uveal melanoma.

Pigment Cell Melanoma Res 2020 05 6;33(3):507-514. Epub 2019 Dec 6.

The Department of Tumor Biology, Moffitt Cancer Center, Tampa, FL, USA.

View Article and Find Full Text PDF
May 2020

Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.

J Biol Chem 2019 08 27;294(33):12459-12471. Epub 2019 Jun 27.

Division of Hematology/Oncology, University of Florida Health Cancer Center, Gainesville, Florida 32608

View Article and Find Full Text PDF
August 2019

Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.

Epigenomes 2018 Sep 3;2(3). Epub 2018 Sep 3.

Division of Hematology and Oncology, Department of Medicine, University of Florida Health Cancer Center, University of Florida, Gainesville, FL 32610, USA;

View Article and Find Full Text PDF
September 2018

Inhibition of cardiomyocyte Sprouty1 protects from cardiac ischemia-reperfusion injury.

Basic Res Cardiol 2019 01 11;114(2). Epub 2019 Jan 11.

Research Unit of Biomedicine, Department of Pharmacology and Toxicology, University of Oulu, P. O. BOX 5000, 90014, Oulu, Finland.

View Article and Find Full Text PDF
January 2019

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.

Cell Rep 2018 12;25(10):2808-2820.e4

Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address:

View Article and Find Full Text PDF
December 2018

DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.

Authors:
Jonathan D Licht

Trans Am Clin Climatol Assoc 2018 ;129:24-36

GAINESVILLE, FLORIDA.

View Article and Find Full Text PDF
December 2018

SETD2: a complex role in blood malignancy.

Authors:
Jonathan D Licht

Blood 2017 12;130(24):2576-2578

UNIVERSITY OF FLORIDA HEALTH CANCER CENTER.

View Article and Find Full Text PDF
December 2017

Loss of Spry1 attenuates vascular smooth muscle proliferation by impairing mitogen-mediated changes in cell cycle regulatory circuits.

J Cell Biochem 2018 04 26;119(4):3267-3279. Epub 2017 Dec 26.

Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine.

View Article and Find Full Text PDF
April 2018

UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.

Cell Rep 2017 Oct;21(3):628-640

Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Division of Hematology/Oncology, University of Florida Health Cancer Center, Gainesville, FL 2033, USA. Electronic address:

View Article and Find Full Text PDF
October 2017

Targeting Epigenetics in Cancer.

Annu Rev Pharmacol Toxicol 2018 01 6;58:187-207. Epub 2017 Oct 6.

Division of Hematology & Oncology, Department of Medicine, University of Florida Health Cancer Center, University of Florida, Gainesville, Florida 32606, USA; email:

View Article and Find Full Text PDF
January 2018

Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.

Curr Opin Hematol 2017 Jul;24(4):336-344

Department of Medicine, Division of Hematology-Oncology and The University of Florida Health Cancer Center University of Florida, Gainesville, Florida, USA.

View Article and Find Full Text PDF
July 2017

The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Cold Spring Harb Perspect Med 2017 Jun 1;7(6). Epub 2017 Jun 1.

Departments of Medicine, Biochemistry and Molecular Biology and University of Florida Health Cancer Center, The University of Florida, Gainesville, Florida 32610.

View Article and Find Full Text PDF
June 2017